Non-alcoholic fatty liver disease (NAFLD) is a prevalent, multifactorial, and poorly understood liver disease with an increasing incidence worldwide. NAFLD is typically asymptomatic and coupled with other symptoms of metabolic syndrome. The prevalence of NAFLD is rising in tandem with the prevalence of obesity. In the Western hemisphere, NAFLD is one of the most prevalent causes of liver disease and liver transplantation. Recent research suggests that gut microbiome dysbiosis may play a significant role in the pathogenesis of NAFLD by dysregulating the gut–liver axis. The so-called “gut–liver axis” refers to the communication and feedback loop between the digestive system and the liver. Several pathological mechanisms characterized the alteration of the gut–liver axis, such as the impairment of the gut barrier and the increase of the intestinal permeability which result in endotoxemia and inflammation, and changes in bile acid profiles and metabolite levels produced by the gut microbiome. This review will explore the role of gut–liver axis disruption, mediated by gut microbiome dysbiosis, on NAFLD development.

Background/Objectives: In metabolic bariatric surgery, structured follow-up protocols may play an essential role in achieving optimal patient outcomes. This study aims to report postoperative biochemical outcomes in a cohort of post-bariatric patients who underwent a structured follow-up protocol. Methods: This retrospective study included patients who underwent metabolic bariatric surgery and completed a one-year follow-up at Cannizaro Hospital from October 2022 to May 2024. Anthropometric, clinical, and laboratory data were collected for each patient at five different timepoints: baseline, 1, 3, 6, and 12 months post-surgery. All data were organized into a database and analyzed through descriptive statistics. Results: The study cohort (n = 80) showed a follow-up adherence equal to 97.5%. The mean value of BMI decreased from 42 to 27 one year after surgery. Lipid profiles improved, with significant reduction in total cholesterol and triglycerides and increase in HDL levels; LDL levels decreased initially but at one year returned to baseline. Thyroid hormones TSH and fT3 decreased significantly, while fT4 remained stable. A reduction in hepatic inflammation was observed, as evidenced by the decrease in GGT and transaminase levels. Pancreatic enzymes showed an initial increase but stabilized at the subsequent timepoints. Glycemic control improved, with statistically significant reductions in insulin, HbA1c, and glucose levels, and complete remission of type 2 diabetes mellitus in affected patients. Conclusions: This study shows significant weight loss and improved health outcomes in post-bariatric patients who underwent a structured follow-up protocol, suggesting the potential benefits of metabolic bariatric surgery.

Laparoscopic cholecystectomy is now established as the worldwide gold standard for the treatment of benign gallbladder disease. Despite technical advancements, bile duct injury (BDI) remains a major concern, especially in patients with obesity. It is well known that in patients with a Body Mass Index (BMI) ≥ 30 kg/m², identification of Calot’s triangle and the achievement of the Critical View of Safety (CVS) during laparoscopic cholecystectomy (LC) are made more challenging due to excessive visceral adiposity and concomitant hepatic steatosis reducing the workspace. Near-Infrared Fluorescence Cholangiography (NIRF-C) with Indocyanine Green (ICG) has emerged as an innovative, safe and effective technique to visualize the biliary anatomy and minimize the risk of iatrogenic BDI. However, its specific benefit in patients with obesity remains under-discussed compared to the general population. The main aim of this narrative review is to evaluate whether the intraoperative use of ICG in patients with obesity may reduce operative times and the risk of BDI. A focused review of the literature is performed on articles from 2010 to 2025 published on PubMed, Scopus and Web of Science. The application of ICG fluorescence in LC for patients with obesity represents a tangible clinical advantage, not only for anatomical identification and significant improvement of procedural efficiency, but also for the reduction in operative time.